Low/Intermediate PCa Video Chat, June 23, 2025

Low/Intermediate PCa Video Chat, June 23, 2025

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.

WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.

Join our other free and drop in groups:
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!

Editor’s Pick: AI improvements may make biopsies unnecessary. (bj)

Topics Discussed
AI improvements with PI-RADS for MRIs and their potential to make biopsies unnecessary; new PCa diagnosis with a personal history of kidney cancer and family history of PCa; micro or nano ultrasound as an alternative to MRI for biopsy guidance (e.g., in cases where MRI is difficult or contraindicated); PROTON vs. CyberKnife: comparison of treatment modalities; Prostox genetic testing to predict genitourinary (GU) toxicity; thoughts and opinions about repeat biopsies and when they are appropriate; transitioning from Active Surveillance to Low/Intermediate PCa treatment; seeking insight into radiation treatment options; biomarkers to defer biopsy (e.g., ExoDx, My Prostate Score 2, EpiSwitch PSE); importance of expert pathology review and specific expert pathologists (e.g., Dr. Jonathan Epstein, Dr. Ming Zhou); philosophy of screening and testing at any age with informed decision-making (e.g., PSA testing for information); SBRT (Stereotactic Body Radiation Therapy) as a treatment type, including CyberKnife as a specific technology; use of Barigel or SpaceOAR to protect the rectum during radiation; boost to Dominant Intraprostatic Lesion (DIL) in radiation and challenges with prostate movement during treatment; genetic markers like HOXB13 and HSD3B1 in PCa diagnosis; Decipher genetic testing and arterial AI as helpful tools; and focal treatment for prostate cancer.

Chat Log

AnCan Barniskis Room
HOXB13

AnCan Barniskis Room
Scott Eggener, uro http://www.uchospitals.edu/physicians/scott-eggener.html

John A
HSD3B1         HOXB13

John A
ming.zhou@mt.sinai.org

John A
advanceduropathology.com

Stuart
Dr. Ming Zhou  Mount Sinai Health System  Department of Pathology, Box 1194  Annenberg Bldg. 15th FL  1468 Madison Ave  New York, NY 10029  Email: Ming.zhou@mountsinai.org  Telephone: (212)241-8881

AnCan Barniskis Room
Dr. Jonathan Epstein  https://advanceduropathology.com/

karl b
kbatschke@gmail.com

karl b
No

AnCan Barniskis Room
Prostox seminar ….. https://ancan.org/event/special-presentation-what-if-you-could-predict-the-risk-of-radiation-effects-prostox-and-beyond/

AnCan Barniskis Room
Don’t see you.

karl b
Just found my genetic testing. Abnormal gene is HOXB13

AnCan Barniskis Room
Thought so – that’s a fairly common mutatiion for cancer that runs in families.

karl b
Thank you all! I have to log off.

AnCan Barniskis Room
Don’t think it means much for treatment. But imprtant for Dx. . Do you have sons, Karl?